Navigation Links
Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
Date:11/1/2010

high-value treatments for infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development. Medivir has a strong R&D portfolio and has recently launched its first product Xerese(TM)/Xerclear(TM). Medivir's key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

Xerese(TM)/Xerclear(TM) is an innovative treatment for cold sores, which has been approved in both the US and Europe. It is partnered with GSK to be sold OTC in Europe and Russia and with Meda in North America. Medivir has retained the Rx rights for Xerclear(TM) in Sweden and Finland.

For more information about Medivir, please visit the Company's website: http://www.medivir.se.

About TMC435 clinical trial programs

TMC435 is a once daily protease inhibitor jointly developed by Medivir and Tibotec Pharmaceuticals to treat hepatitis C virus infections. TMC435 is currently being studied in three phase 2b clinical trials (TMC435-C205, TMC435-C206 and TMC435-C215) in genotype 1 (G1) treatment-naive and in G1 patients that failed previous IFN-based treatment. TMC435 is planned to enter phase 3 studies early 2011.

PILLAR Study (TMC435-C205)

TMC435-C205 is an ongoing randomized double-blind global phase 2b study in 386 genotype-1 treatment-naive patients. It evaluates once daily treatment of TMC435 with different doses and durations given in addition to standard of care treatment, consisting of ribavirin and pegIFNalpha-2A.

ASPIRE Study (TMC435-C206)

TMC435-C206 is an ongoing randomized double-blind global phase 2b study in 463 genotype-1 treatment-experienced patients. It evaluates once daily treatment of TMC435 in with different doses of given in addition to standard of care treatment, consisting of ribavirin and pegIFNalpha-2A.

TMC435-C215

TMC435-C215 is a
'/>"/>

SOURCE Medivir
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Medivir Interim Report, 1 January - 30 September 2010
2. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
3. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
4. Cord Blood America Continues to Reduce Debt; Three Notes Retired
5. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
6. Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest
7. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
8. Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes
9. Stryker Corporation Announces Pricing of Senior Notes
10. Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes
11. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Texas , Sept. 4, 2015  Luminex Corporation ... present at the Morgan Stanley Global Healthcare Conference to ... Grand Hyatt Hotel in New York City ... at 11:40 a.m. Eastern time on Friday, September 18, ... accessed at Luminex Corporation,s website at http://www.luminexcorp.com . ...
(Date:9/4/2015)... 4, 2015 According to a ... Plateletpheresis, Erythrocytapheresis, Leukapheresis, and Photopheresis) by Procedure (Therapeutic Apheresis, ... - Global Forecast to 2020", published by MarketsandMarkets, the ... Billion by 2020, growing at a CAGR of 11.2% ... Browse 139 Tables and 45 F ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... 2011 Par Pharmaceutical Companies, Inc. (NYSE: PRX ... EST on Friday, January 6, 2012 at the Millennium Hotel, ... Executive Officer, Patrick G. LePore, and other members of the ... growth strategy, current products and pipelines, and business outlook to ...
... Calif., Dec. 5, 2011  Beyond Lucid Technologies, Inc., ... disaster management, and First Response industries, today announced ... the mHealth Summit, and the publication of a ... connect ambulances with hospitals via telemedicine. ...
Cached Medicine Technology:Beyond Lucid Technologies Advances Telemedicine for EMS Providers 2Beyond Lucid Technologies Advances Telemedicine for EMS Providers 3
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former ... will compete in the Ironman World Championships in Kona on October 10th. , Mike ... Traumatic Brain Injury (TBI) through combat and the cutting-edge treatments that restore their quality ...
(Date:9/4/2015)... OR (PRWEB) , ... September 04, 2015 , ... ... markets a line of personal humidifying medical devices, announced its only mission and ... explains Bio-Logic Aqua® Research Founder Sharon Kleyne, body water evaporation is becoming dangerously ...
(Date:9/4/2015)... ... 04, 2015 , ... The conference program for the upcoming ... 9-10, 2015 at the Diplomat Resort & Spa has been announced and is ... at the top of their field and will be presenting sessions such as ...
(Date:9/4/2015)... ... 2015 , ... ECC announces the site selection and commencement ... with intellectual, developmental and acquired disabilities. The first community, named Luna Azul, will ... homes. In this community, adults will live safely and permanently in homes owned ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... in South Glastonbury, Connecticut, has been selected for the Residential Award of Merit ... efficiency and resiliency measures. Chosen from a highly competitive field of submissions, the ...
Breaking Medicine News(10 mins):Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2
... (NYSE Amex: FHC ) today announced that it ... results for the second quarter and first half of FY2009 ... 2009. The Company expects to report its second quarter ... day. Shareholders and other interested parties may participate in the ...
... COSTA MESA, Calif., May 1 Oxygen Biotherapeutics, Inc. ... has filed a Cosmetic Product Ingredient Statement (CPIS) with ... product. Oxycyte is the company,s perfluorocarbon (PFC) therapeutic ... sign that we are a big step closer to ...
... after a fall, sudden twist or blow to the ankle joint. ... experience chronic ankle pain, even after being treated for their initial ... 2009 issue of the Journal of the American Academy of ... ankle can be a possible cause for this chronic pain. ...
... Guidelines at the Point of Care-TAMPA, Fla., May ... of drug information applications and clinical information solutions, ... is now providing physicians with the latest treatment ... by the Centers for Disease Control and Prevention ...
... and active Mediterranean lifestyle are curePALM BAY, Fla., May ... likely we are to maintain a healthy diet -- ... than that eaten in the Mediterranean?In his new book, ... published by iUniverse ), Ray Adamcik M.D., ...
... NUTLEY, N.J., May 1 /PRNewswire/ -- ... contributions to industry in New Jersey at the ... Honored were Nancy Shore DiLella, J.D., senior counsel ... the leading hepatitis C treatment, Pegasys(R) (peginterferon alfa-2a); ...
Cached Medicine News:Health News:The Female Health Company Schedules Second Quarter Conference Call for May 8, 2009 2Health News:Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel 2Health News:Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel 3Health News:Chronic ankle pain may be more than just a sprain 2Health News:EMPOWERx E-Prescribing Solution Provides Latest Treatment Guidelines for 2008-2009 H1N1 Influenza Virus 2Health News:'The Globe's Best Diet: The Metabolic Syndrome Cure' 2Health News:Roche Women Honored as 2009 TWIN Awardees 2Health News:Roche Women Honored as 2009 TWIN Awardees 3Health News:Roche Women Honored as 2009 TWIN Awardees 4Health News:Roche Women Honored as 2009 TWIN Awardees 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: